Industry News Sponsored by
Senomyx Inc. narrowed its first-quarter loss and revenue rose 12.6% to $6.8 million as its development revenue grew.
The company's recent updates include:
View the earnings release below or click here.
Senomyx Inc. ended the first quarter with $31.6 million in cash and highly liquid investments.
"We are very pleased with the progress Senomyx has made thus far in 2014," said John Poyhonen, president and CEO of the company. "During the first four months of the year, we have established a new research agreement for our Salt Taste Program, added two new flavor offerings to our direct sales portfolio, and received regulatory authorization for the commercialization of Sweetmyx™ S617 in the United States and certain other markets."
"We are excited about Senomyx's direct sales program, which is gaining momentum with further evaluations of our ingredients by flavor companies, as well as the addition of new offerings," stated Sharon Wicker, Senior Vice President and Chief Commercial Development Officer. "Commercialization activities were initiated recently with Sweetmyx SR69, also known as S6973, which is used to maintain the sweet taste in reduced-sugar products. Sweetmyx SR69 has been granted regulatory approvals in nearly every major country, and it is the first sucrose modifier in our direct sales portfolio being promoted for food usage. It is an excellent complement to Sweetmyx SR96 (S9632), another effective sucrose modifier that we are currently marketing for use with reduced-sugar beverages. In addition, we are receiving positive feedback from evaluations of our Savorymyx™ UM80 savory flavor, which are underway in the U.S. and elsewhere for use in a range of food and beverage products.
"Most recently, Senomyx has started introducing our Bittermyx™ BB68 bitter blocker to potential flavor company customers. Bittermyx BB68 can be used as part of a flavor system for foods and beverages to reduce the bitterness of ingredients such as soy and whey proteins, menthol, caffeine, cocoa, and stevia," Wicker explained. "Reducing the bitterness of high-protein products is especially helpful for manufacturers of the more nutritionally based, higher margin products."
Commercialization Updates: Under the Company's direct sales program, rather than relying solely on licensing collaborations for commercialization, Senomyx also sells certain of its pure, also commonly referred to as "neat", ingredients to flavor companies that can incorporate them into proprietary flavor systems for their customers. Senomyx's internal commercial organization handles sales and marketing, as well as supply chain management of third party manufacturers. The direct sales program complements Senomyx's existing collaborations, which are based on exclusive or co-exclusive commercialization licenses with partners that pay royalties to the Company.
Senomyx Direct Sales Program: Senomyx intends to leverage its proprietary taste science technologies to become a leading commercial provider of novel flavor ingredients to the flavor industry. The Company's Complimyx® Taste Modulation Ingredients brand includes Senomyx's Sweetmyx sweet taste modifiers, Savorymyx savory flavors, and Bittermyx bitter blockers. Sweetmyx ingredients are sweet flavor modifiers used with other flavors to restore the desired sweet taste of products in which sucrose or other sweeteners have been reduced. Having multiple Sweetmyx offerings allows the Company to address specific food or beverage product requirements and broadens the potential applications for Senomyx's flavor ingredient portfolio.
Sweetmyx SR96 (S9632), a sucrose modifier, is currently being evaluated by flavor companies for end-use in non-alcoholic beverages. Commercial-scale quantities of SR96 have been received from the contract manufacturer. Senomyx has begun commercialization activities with a second sucrose modifier, Sweetmyx SR69 (S6973), with a focus on usage for food product categories. Regulatory approvals for SR69 allow commercialization in virtually all countries targeted for marketing. The Company expects to receive initial commercial-scale quantities of SR69 by mid-year 2014.
Savorymyx flavors each provide a distinct new savory (umami) taste sensation and can be combined with other ingredients to create unique new flavor blends. They are applicable for a variety of products including sauces, frozen foods, cooking aids, soups, and snack foods, and can be used to reduce or replace added monosodium glutamate (MSG). Savorymyx UM80 (S807) is being evaluated by flavor companies in the U.S. and elsewhere for use in numerous food and beverage product categories. Senomyx has received commercial inventory quantities of UM80 from a global manufacturer to support the Company's marketing efforts.
Bittermyx bitter blockers are used to reduce the bitterness of ingredients that impart a bitter taste or have a bitter lingering effect such as soy and whey proteins, menthol, caffeine, cocoa, and Rebaudioside A (stevia). Senomyx has initiated evaluations of Bittermyx BB68 (S6821) with flavor companies for multiple potential usages. The Company expects that commercial quantities of BB68 will become available during the third quarter of 2014.
Royalty-Based Collaborations: Senomyx has collaborative agreements with several of the world's leading packaged food, beverage, and ingredient companies. The Company has received commercial revenues on sales of products incorporating its flavor ingredients from Firmenich SA, Nestlé SA, and Ajinomoto Co., Inc.
Upcoming Commercialization: Senomyx's newest Sweetmyx ingredient (S617) is a flavor with modifying properties that is used as part of a flavor system to maintain the taste in a wide variety of foods and beverages in which a sweetener has been reduced. PepsiCo has exclusive rights to use the new flavor ingredient worldwide in non-alcoholic beverages and Firmenich has lifetime rights to commercialize it for food product categories and alcoholic beverages, with exclusive rights until March 2018.
Discovery & Development Program Updates:
Sweet Taste Program: The primary goal of Senomyx's Sweet Taste Program is to add to the Company's portfolio of new flavor ingredients that restore the desired flavor profile to food and beverage products that have a significant reduction in sweeteners. Senomyx is continuing efforts to discover novel flavors with modifying properties that could create incremental value. The Company has identified new modifiers of sucrose and fructose that possess advantageous properties and may help expand the potential market for Senomyx's sweet flavor modifiers portfolio. Evaluations and prioritization of new sweet flavor modifiers that are candidates for development activities are ongoing. The goal of the Natural Products component of Senomyx's Sweet Taste Program is to discover and develop novel no- or low-calorie natural high intensity sweeteners and natural sweet flavor modifiers. The Company has identified taste proofs-of-concept for several natural sucrose modifiers and a natural high intensity sweetener. Continuing activities include further expansion of Senomyx's natural products library, high-throughput screening of these plant-derived samples, and additional taste tests of samples of interest.
Cooling Taste Program: The goal of the Cooling Taste Program is to identify novel cooling agents that have advantages over currently available agents such as menthol. Definitive safety studies and other development activities in preparation for future regulatory filings are underway for S2227, a new cooling agent. Firmenich has exclusive commercialization rights for S2227. Additional new cooling agents are being evaluated for potential future commercialization.
Salt Taste Program: The goal of Senomyx's Salt Taste Program is to identify flavor ingredients that allow a significant reduction of sodium in foods and beverages yet maintain the salty taste desirable to consumers. This program is an important focus for the Company's research activities. Senomyx has been using analytical approaches to evaluate a large proprietary database of proteins found in taste buds in order to find the specific protein or group of proteins that function to detect salt in foods. This protein or proteins can then serve as research targets to discover new salt flavor modifiers using Senomyx's novel flavor technology. Senomyx has identified a small group of proteins that meet certain criteria for potentially being involved in salt taste, and more advanced tests are underway to determine if they function to detect salt. Each of these candidate targets is being further evaluated to see if it modulates salty taste, which would provide a taste proof-of-concept. In April, the Company announced that it had entered into a new research agreement under which PepsiCo will provide research funding for the Salt Taste Program for 2014 and has options to extend the research funding period. PepsiCo will have non-exclusive rights to salt flavor modifiers discovered during the research funding period. In addition, Senomyx will have the right to supply these flavor ingredients directly to PepsiCo.
Intellectual Property: Senomyx continues to be diligent in seeking protection for its intellectual property. As of March 31, 2014, the Company is the owner or exclusive licensee of 426 issued patents and several hundred pending patent applications in the U.S., Europe, and elsewhere related to proprietary taste science technologies.
At March 31, 2014, Senomyx held $31.6 million in cash, cash equivalents and investments available-for-sale. Total revenues were $8.2 million for the first quarter ended March 31, 2014, compared to $7.5 million for the first quarter ended March 31, 2013. The increase primarily resulted from $1.3 million of development milestones earned in the first quarter of 2014 related to the Sweet Taste Program. This increase was partially offset by a decrease in development revenues related to Senomyx's Cooling Taste Program, as research funding under the Company's collaboration with Firmenich expired in June 2013. Research, development and patents expenses, including stock-based compensation expenses, were $7.0 million for the first quarter of 2014 compared to $7.4 million in the first quarter of 2013. The primary factor for the decrease from 2013 to 2014 was reduced outside services costs for safety studies to support regulatory filings. Selling, general and administrative expenses, including stock-based compensation expenses, were $3.1 million for the first quarter of 2014 and $3.0 million for the first quarter of 2013. The increase was primarily due to increased non-cash stock-based compensation expenses in 2014 resulting from a higher fair value for stock options granted in 2014 based on the higher price of Senomyx's common stock. The net loss for the quarter ended March 31, 2014 was $0.05 per share, compared to $0.07 per share for the quarter ended March 31, 2013.
Financial Outlook: "Financial results for the first quarter of 2014 met or exceeded management expectations and we are on-track to achieve our financial guidance," stated Tony Rogers, Senior Vice President and Chief Financial Officer.
For the full year 2014, Senomyx continues to expect:
"During the first quarter we recorded revenue associated with direct sales to flavor companies. While these initial sales were modest, we continue to make promising incremental progress and we expect that direct sales will be a key driver of commercial revenue growth in the future. With $31.6 million in cash and no debt, Senomyx remains well-positioned to achieve our discovery, development and commercialization objectives, including our goal of approximately $25 million in commercial revenues in 2015 and, importantly, achieving profitability in 2015. Furthermore, we have no plans to raise money through the issuance of equity or debt to fund the current scope of our operations," Rogers concluded.
In addition to ending the first quarter 2014 with approximately $31.6 million in cash and highly liquid investments, going forward the Company has committed and potential sources of cash under current collaborations including the following: $15 million in committed development payments $18 million in potential development payments related to extension options $28 million in potential milestone payments.